2105 Laekna, Inc. HKEX · China

Laekna (2105) news

Laekna, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2105, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Laekna news

We have not published a story on Laekna yet. When there is news, it will appear here.

Questions about Laekna

What is the ticker symbol of Laekna?

Laekna, Inc. trades under the ticker 2105 on HKEX.

Where is Laekna listed?

Laekna, Inc. is listed on HKEX.

Which country or territory is Laekna listed under?

Our directory records Laekna, Inc. under China.

What does Laekna do?

Our directory classifies Laekna, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Laekna?

The ISIN recorded for Laekna, Inc. is KYG5340S1093.

Does aibio.space cover Laekna?

aibio.space lists Laekna, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Laekna?

Companies in our directory listed in the same country and business area as Laekna: Qyuns Therapeutics Co., Jacobio Pharmaceuticals Group Co., Qingdao Vland Biotech INC., Zhejiang Hengtong Holding Co., Beijing Luzhu Biotechnology Co., Shanghai Shen Lian Biomedical.

Investor discussion: Laekna

Members talk about Laekna (2105). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Laekna, newest first. Each line links the filing it comes from.

Sep 17, 2025Financings
Share or debt issue: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source
Sep 9, 2025Financings
Share or debt issue: PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source
Nov 27, 2024Financings
Share or debt issue: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source
Nov 21, 2024Financings
Share or debt issue: PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source

Press releases

Headlines of Laekna's own announcements, newest first. Each opens the full release on the newswire that carried it.

Oct 13, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT UPDATES ON THE 24-WEEK MONOTHERAPY STUDY OF LAE102 SHOWED PROMISING WEIGHT LOSSES FAVORABLE CHANGES IN BODY COMPOSITION AND WELL TOLERATED SAFETY PROFILE
Sep 1, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE PHASE I CLINICAL STUDY OF LAE118 (A NOVEL PI3K ALPHA PAN-MUTANT SELECTIVE INHIBITOR)
Aug 25, 2026HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR SIX MONTHS ENDED JUNE 30, 2026
Aug 17, 2026HKEXnews
POSITIVE PROFIT ALERT
Aug 12, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR LAE002 (AFURESERTIB) WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Jul 2, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT PROPOSED ON-MARKET SHARE REPURCHASES UNDER THE REPURCHASE MANDATE AND PROPOSED SHARE PURCHASE BY SENIOR MANAGEMENT
Jun 29, 2026HKEXnews
UPDATE ON QUALIFICATION OF COMPANY SECRETARY; RESIGNATION OF JOINT COMPANY SECRETARY AND CHANGE OF AUTHORISED REPRESENTATIVE
Jun 10, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT WITH VASQUE BIO FOR LAE118 (A NOVEL PI3K ALPHA PAN-MUTANT SELECTIVE INHIBITOR) IN EX-CHINA REGION
Jun 5, 2026HKEXnews
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2026
May 14, 2026HKEXnews
NOTICE OF ANNUAL GENERAL MEETING
May 8, 2026HKEXnews
GRANT OF RESTRICTED SHARE UNITS
Apr 15, 2026HKEXnews
INSIDE INFORMATION POSITIVE TOPLINE RESULTS PHASE III CLINICAL TRIAL (AFFIRM-205) OF LAE002 (AFURESERTIB) MET PRIMARY ENDPOINT OF PFS DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL BENEFITS IN PATIENTS WITH PIK3CA/AKT1/PTEN ALTERATIONS AND HR+/HER2- LA/mBC
Mar 18, 2026HKEXnews
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Mar 10, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT POSITIVE TOPLINE RESULTS FROM U.S. PHASE I SAD STUDY OF LAE102 SHOWED ENCOURAGING TRENDS TOWARD LEAN MASS INCREASE AND FAT MASS REDUCTION
Jan 14, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT THE U.S. FOOD AND DRUG ADMINISTRATION ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LAE118
Dec 31, 2025HKEXnews
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT DOSED IN PHASE I SINGLE ASCENDING DOSE STUDY OF LAE103
Dec 22, 2025HKEXnews
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT DOSED IN PHASE I MULTIPLE DOSE EXPANSION STUDY OF LAE102 FOR THE TREATMENT OF OBESITY
Dec 15, 2025HKEXnews
VOLUNTARY ANNOUNCEMENT COMPLETION OF PATIENT ENROLLMENT IN PHASE III CLINICAL TRIAL (AFFIRM-205) OF LAE002 (AFURESERTIB) IN HR+/HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Dec 12, 2025HKEXnews
Terms of Reference for the Nomination and Corporate Governance Committee
Dec 12, 2025HKEXnews
CHANGE OF THE COMPOSITION OF THE NOMINATION AND CORPORATE GOVERNANCE COMMITTEE

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2105 on TradingView.

Listing details

Company: Laekna, Inc.
Ticker: 2105
Listing: HKEX
Country or territory: China
Business scope: Biotechnology
ISIN: KYG5340S1093
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction